Overview
Babylon combined mobile health tools with access to clinicians, then expanded into US contracts that made it responsible for wider patient-care costs. The original group failed in 2023 after a proposed rescue collapsed. Its UK clinical services continued under eMed. Patients kept receiving care through an acquired business. [1][2][3]
The central business problem was the gap between growth and the cash needed to support care. Technology could make access easier, but it did not remove clinical labor, medical claims, or financing risk. The surviving services also caution against treating the collapse as proof that every part of the product lacked value.
Founding Story
Ali Parsa founded Babylon in 2013. His legal name, Ali Parsadoust, appears in the annual filing. The Jersey holding company was incorporated in 2014, with its principal executive offices in London. Founding and holding-company incorporation should not be collapsed into one date. [4]
In the June 2021 public-listing announcement, Parsa described “combining the latest in technology and the best in medical expertise.” The planned merger implied a $4.2 billion equity value and estimated $575 million of gross proceeds. Both numbers described the proposed transaction, rather than cash already available. [5]
The completed October announcement reported approximately $460 million of proceeds before transaction expenses, combining the business combination and AlbaCore sustainability-linked notes transaction. That total included debt and should not be described as pure equity funding. Parsa said, “we believe we are only just getting started.” His language reflected the intended expansion, rather than an established profitable model. [6]
Timeline
- 2013–2014: Founded, followed by the Jersey holding company's incorporation. [4]
- 2017: GP at Hand brought a digital-first approach to an NHS general practice. [4]
- 2018: The Royal College of Physicians called for stronger real-world evidence for medical AI. [8]
- October 2021: Babylon completed its public-market transaction. [6]
- 2022: US care contracts drove revenue growth while operating cash use remained substantial. [1]
- August 2023: MindMaze rescue fell through; US exit and UK sale efforts followed. [2]
- October 2023: eMed publicly confirmed the UK clinical subsidiary and selected asset acquisition. [3]
- 2025–2026: GP at Hand continued as an NHS partnership, with eMed providing some services under subcontract. [9][10]
What They Built
Babylon offered several things under one name. Its digital tools provided health information, while clinical services connected patients to practitioners. GP at Hand combined remote appointments with in-person care. NHS England's historical fact sheet described an NHS practice offering both forms of consultation, free at the point of use. [7]
The clinical service employed doctors. The Care Quality Commission's archived December 2019 inspection summary described remote GP consultations, prescribing, and approximately 150 salaried doctors. It rated that inspected service Good overall. That dated assessment does not certify every algorithm or every later service, but it is meaningful counterevidence to an account that dismisses all care delivery. [11]
The AI claims required their own scrutiny. In July 2018, the Royal College of Physicians clarified that supplying scenarios to Babylon was not a joint project. It called for stronger trials with real patients and stressed doctors' continuing role. This is a narrower conclusion than either institutional endorsement or proof that all automated health tools are unsafe. [8]
US expansion changed the operating exposure. Under value-based care contracts, Babylon received payments per member and could bear excess medical costs. Its filing said this revenue did not depend on how often members used the digital platform. A covered member was therefore not necessarily an active app user. [1]
Market Position
Target Customers
The company served patients, but governments, insurers, employers, and health providers could fund access. Each buyer had different obligations and economics. An NHS practice, a private consultation service, and a US medical-risk contract cannot be evaluated as interchangeable subscriptions. [2][7]
Market Size
Contracts, clinical capacity, patient needs, and assigned costs defined the practical market. The evidence does not establish an independently verified market size for a profitable version of its combined model.
Competition
Digital access now competes with existing clinical services and established workflow software. Current GP at Hand terms distinguish clinician-delivered care from informational digital services. Accurx's current procurement documents cover patient communication, online requests, and booking, with prices tied to the patient list and selected modules. A new entrant must show a specific benefit beyond those existing tools. [12][13]
Business Model
For calendar 2022, the US GAAP filing reported $1.110 billion revenue, including $1.026 billion of value-based care revenue, and $1.017 billion of claims expense. Net loss was $221.4 million; net cash used in operating activities was $311.4 million. These are different financial measures. The large revenue figure mostly represented a care operation carrying medical-cost exposure, rather than high-margin software sales. [1]
Alvarez & Marsal's own deal account described a business with more than $1 billion turnover, a roughly $15 million monthly burn rate, and approximately $200 million further funding needed to reach breakeven. Those are its transaction-period assessment, not a lifetime funding total or an independently guaranteed forecast. [14]
Outcome and evolution
On August 7, 2023, Babylon said the proposed AlbaCore/MindMaze combination would not proceed. After bridge funding, it had no binding commitment for additional finance. It announced its core US exit and pursued sales, warning that sale proceeds were not expected to cover AlbaCore indebtedness or leave payments for ordinary shareholders. [2]
Customer concentration compounded the disruption. An August filing recorded Centene's non-renewal notice, followed by immediate termination of most contracts after the announced US exit. Three agreements with the independent physician association business were excluded. The wider Centene agreements represented 48.1% of 2022 revenue. The sequence supports concentration risk; it does not justify claiming that every Centene contract ended or that termination alone caused the collapse. [15]
The UK sale preserved an operating service. The adviser described a pre-pack sale; eMed later confirmed acquiring Babylon Healthcare Services Limited and certain assets of two other entities. Its announcement included continuing NHS GP at Hand services. This was a defined subsidiary and asset transaction, rather than the entire original parent surviving intact. [14][3]
Current practice documents make the relationship more precise. GP at Hand describes itself as an NHS GP partnership. Its partnership page identifies Babylon Healthcare Services, trading as eMed, as a subcontractor for some appointments. The June 2025 patient leaflet describes remote care, clinics, and practice governance. These records support continuity without treating the NHS practice as an app owned outright by the former parent. [9][10]
Parsa subsequently founded a separate venture, Quadrivia. Its current indexed company page names him founder and CEO and describes a managed clinical-workflow service. That is a new company's positioning, not a verified revival of Babylon or evidence that its economics have been solved. [16]
Key Lessons
Read what the revenue represents. Payments carrying medical claims risk have different margins and working-capital needs from software licenses. Growth can increase obligations alongside revenue.
Keep clinical evidence specific. A regulator's service inspection, a test scenario, and a real-world algorithm evaluation answer different questions. None should silently stand in for another.
Fund continuity before expansion. Care cannot pause safely when a financing proposal fails. Model the committed cash and transition obligations before adding more patients or contracts.
Follow the legal operating boundary. The original group, a clinical subsidiary, an NHS partnership, and a new founder venture can have different outcomes. Preserving that distinction explains both the failure and what continued.
Sources
[1] 2022 US GAAP annual filing [2] Failed rescue and strategic alternatives, August 2023 [3] eMed completed acquisition announcement, October 2023 [4] 2021 annual filing, reproduced PDF [5] Original proposed listing announcement, June 2021 [6] Company completed transaction release, reproduced SEC exhibit [7] NHS England historical GP at Hand fact sheet [8] Royal College of Physicians clarification, July 2018 [9] Current GP at Hand partnership page [10] GP at Hand patient leaflet, June 2025 [11] Archived CQC inspection summary, December 2019 [12] Current GP at Hand terms [13] Accurx June 2026 pricing document, including non-sale appendix [14] Alvarez & Marsal transaction account [15] Centene contract termination filing, August 2023 [16] Quadrivia company page, indexed official text [17] The National: August 2023 report and company-credited product image